Life‑saving cell and gene therapies exist. For half the world, they're still impossible to reach. REALM Bio is building the infrastructure, logistics, and teams to change that by delivering treatment at the point of care, everywhere.
Advanced Therapy Medicinal Products (ATMPs) can rewrite genetic disease and force aggressive cancers into lasting remission. Yet, because global logistics never evolved past the standards built for mass-produced, shelf-stable drugs, our current systems are structurally incapable of delivering living cellular biologics at scale.
This failure to adapt has created a system trapped by compounding frictions: unsustainable centralized pricing that forces successful cures to be withdrawn from major markets, severe geographic care deserts that economically exclude rural populations, fatal waitlist bottlenecks caused by centralized manufacturing queues, and a massive communication gap leaving half of community oncologists completely unaware of advanced treatment options.
Forced into a legacy supply chain, revolutionary medicine becomes an operational impossibility.
Delivering advanced therapies to an underserved global patient population takes a coordinated chain of specialists working to one standard. REALM Bio is building a Unified Partners network to bring the promise of these therapies directly to the patient.
We invite providers across clinical research, analytical, logistics, manufacturing, training, and technology to learn more about our Unified Partners program.
Explore Unified Partners →The Global Access Alliance for Advanced Therapies (GAAAT) is a registered 501(c)(3) public charity affiliated with REALM Bio. It acts as our foundational community anchor, ensuring that access to advanced treatments is sustainable, affordable, and rooted in community trust.
While clinical science solves the disease, GAAAT solves the social and educational framework around it. By partnering with experts, local providers, and patient advocates, we build clinical and biotechnology trust where it is needed most.
GAAAT actively drives our training and workforce development programs to qualify local clinicians, technicians, and operations teams, establishing durable, self-sustaining healthcare ecosystems rather than clinical extraction.
GAAAT operates at the intersection of medical policy, local communities, and biopharma developers to lower clinical trial cost barriers, develop self-sustaining domestic diagnostics, and earn institutional trust.
Visit globalaccessalliance.org →The items below are grouped by where each one stands today. Nothing here is operating unless the label says so.
A proof-of-concept run tested whether a mobile, decentralized cleanroom could hold sterility during production. Every sample came back negative.
ARC², the platform's controlled-environment transport technology, is built on insulation IP licensed from NASA.
We analyzed more than 10,000 treatment facilities to map where access to advanced therapy breaks down.
Boston Labs runs a clinical storage and distribution depot in the Greater Boston biotech cluster and serves as the platform's standing logistics partner. Open for first client. (bostonlabs.com)
The hub-and-spoke design for on-site manufacturing is specified and staged for buildout.
The self-contained mobile manufacturing unit is specified. It is not yet built.
The vetting queue for long-term service providers is open for applications.
A first decentralized pilot is in partner discussions. No site is committed yet.
REALM Bio does not operate as an isolated logistical pipeline. We are positioned within a sophisticated, multi-disciplinary network of scientific holding companies, world-class analytical labs, non-profit advocates, and clinical research frameworks.
This unified corporate ecosystem ensures that we have direct, unhindered access to cutting-edge biotechnological developments, clinical trial protocols, community education, and local analytical validation structures.
Click on any affiliated organization on the right to learn more about how they unite to form our core operational framework.
Our parent biotech holding company. Ministry of Science, Inc. acts as the funding, administrative, and strategic engine driving our operational focus on decentralized medical and scientific access.
Providing high-science facility co-location and laboratory assets. Boston Labs anchors the rigorous biological testing, biomarker screening, and process releasing operations under ¹REALM.
The Global Access Alliance for Advanced Therapies. Our affiliated 501(c)(3) non-profit public charity driving structural patient advocacy, local public policy, and clinical workforce training programs.
Our integrated clinical trial research framework, facilitating robust site qualification, coordinating trial protocols, and verifying regulatory alignment inside low-resource healthcare regions.
Effective Date: May 26, 2026
Welcome to the REALM Bio website (the "Site"). The Site is owned and operated by REALM Bio, a subsidiary of Ministry of Science, Inc. By accessing or using this Site, you agree to comply with and be bound by these Terms of Use. If you do not agree to these terms, you should not access or use this Site.
The contents of this Site are provided for informational and clinical feasibility assessment purposes only. The information regarding logistics lanes, clinical timelines, point-of-care manufacturing, and local trials does not constitute final regulatory, operational, medical, or legal advice. Final protocol execution requires custom, written agreements between REALM Bio and its biopharma clients or sponsors.
All materials, trademarks, logos, diagrams, text, and visual designs regarding the ¹REALM Unified Services Platform and the GAAAT networks are the sole intellectual property of REALM Bio, Ministry of Science, Inc., or their respective partners, and are protected by applicable trademark, copyright, and patent laws. No unauthorized duplication, framing, or distribution is permitted.
While we endeavor to keep all statistics and logistics timelines (including our TrialPath simulation frameworks) accurate and up to date, REALM Bio and Ministry of Science, Inc. make no guarantees or warranties of any kind, express or implied, regarding the readiness, viability, or legality of specific lanes under sudden geopolitical, weather, or supply chain variances.
These Terms of Use shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to its conflict of law principles. Any dispute arising out of or related to these terms shall be subject to the exclusive jurisdiction of the state and federal courts located in Delaware.
Effective Date: May 26, 2026
At REALM Bio, we are fully committed to protecting your privacy and securing the integrity of all biological and logistical data. This Privacy Notice describes our practices regarding information collected through our Site.
This website does not employ third-party tracking scripts, advertising pixels, or invasive tracking cookies. We utilize only essential, temporary session cookies necessary to power our organic grid overlay interface and high-performance HTML5 Canvas rendering engine.
For any analytical or feasibility inquiries submitted to our team (or run through our TrialPath simulations), we explicitly state that no protocol-identifying patient data or HIPAA-protected health information is requested, processed, or stored. All entries are run fresh and immediately discarded.
Information provided voluntarily via direct email partnerships or contact requests (such as name, organization, and partnership scope) is used solely to coordinate partnership feasibility. We will never sell, lease, or distribute your email address or business parameters to outside marketing entities.
Given the global nature of advanced cell and gene therapies, we anchor our physical systems and information practices in strict alignment with GDPR, HIPAA, and relevant international biological chain-of-identity data security standards.